title: Characterization of the novel broad-spectrum kinase inhibitor CTx-0294885 as an affinity reagent for mass spectrometry-based kinome profiling.
abstract: Kinase enrichment utilizing broad-spectrum kinase inhibitors enables the identification of large proportions of the expressed kinome by mass spectrometry. However, the existing inhibitors are still inadequate in covering the entire kinome. Here, we identified a novel bisanilino pyrimidine, CTx-0294885, exhibiting inhibitory activity against a broad range of kinases in vitro, and further developed it into a Sepharose-supported kinase capture reagent. Use of a quantitative proteomics approach confirmed the selectivity of CTx-0294885-bound beads for kinase enrichment. Large-scale CTx-0294885-based affinity purification followed by LC-MS/MS led to the identification of 235 protein kinases from MDA-MB-231 cells, including all members of the AKT family that had not been previously detected by other broad-spectrum kinase inhibitors. Addition of CTx-0294885 to a mixture of three kinase inhibitors commonly used for kinase-enrichment increased the number of kinase identifications to 261, representing the largest kinome coverage from a single cell line reported to date. Coupling phosphopeptide enrichment with affinity purification using the four inhibitors enabled the identification of 799 high-confidence phosphosites on 183 kinases, ∼10% of which were localized to the activation loop, and included previously unreported phosphosites on BMP2K, MELK, HIPK2, and PRKDC. Therefore, CTx-0294885 represents a powerful new reagent for analysis of kinome signaling networks that may facilitate development of targeted therapeutic strategies. Proteomics data have been deposited to the ProteomeXchange Consortium ( http://proteomecentral.proteomexchange.org ) via the PRIDE partner repository with the data set identifier PXD000239.
authors.affiliation: Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Sydney, New South Wales 2010, Australia.
authors.forename: Luxi
authors.initials: L
authors.lastname: Zhang
authors.forename: Ian P
authors.initials: IP
authors.lastname: Holmes
authors.forename: Falko
authors.initials: F
authors.lastname: Hochgräfe
authors.forename: Scott R
authors.initials: SR
authors.lastname: Walker
authors.forename: Naveid A
authors.initials: NA
authors.lastname: Ali
authors.forename: Emily S
authors.initials: ES
authors.lastname: Humphrey
authors.forename: Jianmin
authors.initials: J
authors.lastname: Wu
authors.forename: Melanie
authors.initials: M
authors.lastname: de Silva
authors.forename: Wilhelmus J A
authors.initials: WJ
authors.lastname: Kersten
authors.forename: Theresa
authors.initials: T
authors.lastname: Connor
authors.forename: Hendrik
authors.initials: H
authors.lastname: Falk
authors.forename: Lynda
authors.initials: L
authors.lastname: Allan
authors.forename: Ian P
authors.initials: IP
authors.lastname: Street
authors.forename: John D
authors.initials: JD
authors.lastname: Bentley
authors.forename: Patricia A
authors.initials: PA
authors.lastname: Pilling
authors.forename: Brendon J
authors.initials: BJ
authors.lastname: Monahan
authors.forename: Thomas S
authors.initials: TS
authors.lastname: Peat
authors.forename: Roger J
authors.initials: RJ
authors.lastname: Daly
mesh_terms: D002460:Cell Line; D002853:Chromatography, Liquid / Q000379:methods; D006801:Humans; D010766:Phosphorylation / Q000187:drug effects; D010770:Phosphotransferases / Q000302:isolation & purification*; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D040901:Proteomics; D011743:Pyrimidines / Q000737:chemistry*; D053719:Tandem Mass Spectrometry / Q000379:methods; D062367:ortho-Aminobenzoates / Q000737:chemistry*
chemical_list: C586453:CTx-0294885; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D062367:ortho-Aminobenzoates; D010770:Phosphotransferases; C030986:pyrimidine